Compare ING Groep NV (ING) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs TG Therapeutics Inc — how do they compare? ING Groep NV trades at $35.34 (market cap $101.22B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: ING Groep NV is far larger — about 13.2× TG Therapeutics Inc's market cap, and ING Groep NV pays a 3.73% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ING | TGTX | |
|---|---|---|
Market Cap | $101.22B | $7.64B |
Sector | Financials | Health |
52-Week High | $35.92 | $59.06 |
52-Week Low | $23.66 | $26.94 |
Dividend Yield | 3.73% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $35.66, up 1.19% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 forecast. Revenue growth is steady, reaching $22.90B in 2025, and the company recently raised its 2026-2027 outlook, driven by robust net interest income and lending growth. A dividend of $0.46 per share is scheduled for payment on August 17, 2026.
The outlook for ING is positive, supported by upward earnings revisions, a favorable valuation with a P/E of 13.24, and institutional bullishness. Key risks include persistent negative operating cash flows and sensitivity to interest rate changes. The stock's momentum and fundamental strength present a compelling case for growth-oriented investors, though cash flow trends warrant monitoring.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
